Japanese Clinical Practice Guidelines for Vascular Anomalies 2017

Mimura, Hidefumi; Akita, Sadanori; Fujino, Akihiro; Jinnin, Masatoshi; Ozaki, Mine; Osuga, Keigo; Nakaoka, Hiroki J.; Morii, Eiichi; Kuramochi, Akira; Aoki, Yoko; Arai, Yasunori; Aramaki, Noriko; Inoue, Masatoshi; Iwashina, Yuki; Iwanaka, Tadashi; Ueno, Shinji; Umezawa, Akihiro; Ozeki, Michio; Ochi, Junko; Kinoshita, Yoshiaki; Kurita, Masanori; Seike, Shien; Takakura, Nobuyuki; Takahashi, Masato; Tachibana, Takao; Chuman, Kumiko; Nagata, Shuji; Narushima, Mitsunaga; Niimi, Yasunari; Nosaka, Shunsuke; Nozaki, Taiki; Hashimoto, Kazuki; Hayashi, Akira; Hirakawa, Satoshi; Fujikawa, Atsuko; Hori, Yumiko; Matsuoka, Katsuyoshi; Mori, Hideki; Yamamoto, Yuki; Yuzuriha, Shunsuke; Rikihisa, Naoaki; Watanabe, Shôji; Watanabe, Shinichi; Kuroda, Takeshi; Sugawara, Shunsuke; Ishikawa, Kosuke; Sasaki, Satoshi

doi:10.1111/1346-8138.15189

Cited by 14 publications

(16 citation statements)

References 350 publications

(835 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CMs may occur as a component of Sturge-Weber syndrome, Klippel-Trenaunay syndrome, and other syndromes such as CLOVES and Beckwith-Wiedemann ( Table 1 ) [ 1 , 3 , 10 ]. CMs are treated with PDL beginning in infancy [ 17 , 18 ].…”

Section: Differential Diagnosis Of Ihmentioning

confidence: 99%

See 1 more Smart Citation

Update on infantile hemangioma

Jung

2021

Clin Exp Pediatr

View full text Add to dashboard Cite

The International Society for the Study of Vascular Anomalies classifies vascular anomalies into vascular tumors and vascular malformations. Vascular tumors are neoplasms of endothelial cells, among which infantile hemangiomas (IHs) are the most common, occurring in 5-10% of infants. Glucose transporter-1 protein expression in IHs differs from that of other vascular tumors or vascular malformations. IHs are not present at birth but are usually diagnosed at 1 week to 1 month of age, rapidly proliferate between 1 and 3 months of age, mostly complete proliferation by 5 months of age, and then slowly involute to the adipose or fibrous tissue. Approximately 10% of IH cases require early treatment. The 2019 American Academy of Pediatrics clinical practice guideline for the management of IHs recommends that primary care clinicians frequently monitor infants with IHs, educate the parents about the clinical course, and refer infants with high-risk IH to IH specialists ideally at 1 month of age.High-risk IHs include those with life-threatening complications, functional impairment, ulceration, associated structural anomalies, or disfigurement. In Korea, IHs are usually treated by pediatric hematology-oncologists with the cooperation of pediatric cardiologists, radiologists, dermatologists, and plastic surgeons. Oral propranolol, a non-selective betaadrenergic antagonist, is the first-line treatment for IHs at a dosage of 2-3 mg/kg/day divided into two daily doses maintained for at least 6 months and often continuing until 12 months of age. Topical timolol maleate solution, a topical non-selective beta-blocker, may be used for small superficial type IHs at a dosage of 1-2 drops of 0.5% gel-forming ophthalmic solution applied twice daily. Pulse-dye laser therapy or surgery is useful for the treatment of residual skin changes after IH involution.

show abstract

Section: Differential Diagnosis Of Ihmentioning

confidence: 99%

“…As some AVMs are progressive, leading to significant morbidity and even mortality, an early diagnosis and multidisciplinary team approach are necessary. AVMs and arteriovenous fistula are treated with embolization and/or surgery [ 3 , 5 , 17 , 18 , 27 ].…”

Section: Differential Diagnosis Of Ihmentioning

confidence: 99%

Update on infantile hemangioma

Jung

2021

Clin Exp Pediatr

View full text Add to dashboard Cite

show abstract

“…The pathogenic stimuli including infection, hormone variation, injury and so on can expand the malformations. 7,10,54 The administration dose is recommended starting from 1 mg/kg/day to cardiovascular proper 2-3 mg/kg/day in many published clinical guidelines 8,11,57,64 (Table 2). Based on existent articles, the target dosage is using the empirical maximal dosage of 2-3 mg/kg/day to treat IHs.…”

Section: Use Of Propranolol In Ihsmentioning

confidence: 99%

Propranolol in the Treatment of Infantile Hemangiomas

Tan¹,

Guo²,

Wang³

2021

CCID

View full text Add to dashboard Cite

Propranolol, as the first generation of β-blocker family, was initially introduced in the clinical application for tachycardia and hypertension in the 1960s. However, the occasional discovery of propranolol in the involution of infantile hemangiomas (IHs) brought us a new perspective. IHs are the most common infantile tumor, affecting 4–10% newborns. So far, oral propranolol is the first-line medication for IHs treatment. At the same time, local injection and topical propranolol are developing. Despite the worldwide application, the precise mechanism of propranolol of IHs has not been completely studied. In this article, we reviewed and summarized the current information on pharmacology, mechanism, efficacy, and adverse effects of propranolol. Novel design of biomaterials and bioactive molecules are needed for new treatment and ideal pathway to attain the minimal effective treatment concentration and eliminate the adverse effects.

show abstract

“…As a result, a corresponding spatial defect and scars might occur after the tumor is removed. 2 It is difficult to combine large tumor resection and aesthetics in one-time surgery. This has always been an arduous challenge for doctors.…”

Section: Introductionmentioning

confidence: 99%

“…Maxillofacial AVMs, especially located in sensitive parts of the nose and lips, can protrude the epidermis, squeeze the surrounding tissues, and even erode the bone tissue. As a result, a corresponding spatial defect and scars might occur after the tumor is removed 2 . It is difficult to combine large tumor resection and aesthetics in one‐time surgery.…”

Section: Introductionmentioning

confidence: 99%

Microwave Ablation for Refractory Giant Maxillofacial Arteriovenous Malformation: A Case Report

et al. 2023

View full text Add to dashboard Cite

Maxillofacial arteriovenous malformation located in the sensitive parts of the nose and lips has been an arduous challenge for doctors to meet a balance between resection and aesthetics in one time. In this report, one patient with a giant arteriovenous malformation covering the forehead, the nose, the lip, and bilateral cheeks and resulting in the appearance of the face like a lion's face, can not meet satisfactory outcomes by other therapeutic methods. We successfully reduced the size of vascular lesion using low‐power and short‐duration microwave ablation under real‐time ultrasound guidance. In the two‐year follow‐up, the patient's face almost recovered to normality. Microwave ablation is expected to be a new alternative therapy for the treatment of maxillofacial arteriovenous malformations. Laryngoscope, 2023

show abstract

Japanese Clinical Practice Guidelines for Vascular Anomalies 2017

Cited by 14 publications

References 350 publications

Update on infantile hemangioma

Update on infantile hemangioma

Propranolol in the Treatment of Infantile Hemangiomas

Microwave Ablation for Refractory Giant Maxillofacial Arteriovenous Malformation: A Case Report

Contact Info

Product

Resources

About